PedAM
Pediatric Disease Annotations & Medicines
| Disease | myocardial infarction |
| Symptom | C0264716|chronic heart failure |
| Sentences | 9 |
| PubMedID- 23139624 | This effect may be used to reduce workload on the heart and hence oxygen demands, so that the drug is indicated for secondary prevention of myocardial infarction, adjunctive therapy in patients with stable chronic heart failure, and for the treatment of hypertension and angina pectoris.1,2 in addition, β1-selective blockers prevent the release of renin, a hormone produced by the kidneys that causes constriction of blood vessels. |
| PubMedID- 24339455 | chronic heart failure, as a result of acute myocardial infarction, is a leading cause of death worldwide. |
| PubMedID- 22419888 | Exogenous hydrogen sulfide (h2s) leads to down-regulation of inflammatory responses and provides myocardial protection during acute ischemia/reperfusion injury; however its role during chronic heart failure (chf) due to myocardial infarction (mi) is yet to be unveiled. |
| PubMedID- 22873828 | Inclusion of a supervised outpatient cardiac rehabilitation program is clearly more cost-effective than not including cardiac rehabilitation program (“usual or standard care”) into the overall management of patients after myocardial infarction or those with chronic heart failure. |
| PubMedID- 24282249 | Risks associated with exercise training and testing are sudden cardiac death associated with ventricular arrhythmias, acute myocardial infarction, and in patients with chronic heart failure, pulmonary oedema and deterioration in left ventricular function.73 the last is only found in one study from 198874 and has not subsequently been demonstrated in larger studies.7576 in a recent french study of more than 25 000 patients with ischaemic heart disease, one-third with chronic heart failure found the risk of cardiac complications at 1:8500 exercise testing and 1:50 000 patient exercise hours.77 increasing exercise intensity and age are risk indicators. |
| PubMedID- 21749886 | Trials in patients after myocardial infarction and with chronic heart failure have seen limited and mixed success, probably because of the various cell types and methods used. |
| PubMedID- 23799145 | myocardial infarction (mi) with resultant chronic heart failure (chf) is a leading cause of mortality and morbidity in developed countries. |
| PubMedID- 22919539 | Aldosterone increases angiotensin-converting enzyme and at1 receptor in the paraventricular nucleus (pvn) of the hypothalamus in chronic heart failure with postmyocardial infarction . |
| PubMedID- 25133170 | Sudden cardiac death is the main cause of mortality in patients affected by chronic heart failure (chf) and with history of myocardial infarction. |
Page: 1